Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Similarly, if the proposed rule changes are adopted, the Judicial Conference will have signed off on a constitutionally problematic solution to a nonexistent problem and needlessly injected the ...

Every day it’s a new issue for the most recent installment of this highly coveted franchise. Forget the controversies regarding maps, movement mechanics, and many more, the game right now is overly ...